Laboratory Medicine Program

Thyroid Carcinoma

Clinical Decription:
Thyroid cancers may be histologically classified as differentiated thyroid cancer (DTC, which includes papillary thyroid cancer [PTC], follicular thyroid cancer [FTC], and Hürthle cell cancer); anaplastic thyroid cancer (ATC); or medullary thyroid cancer (MTC). Papillary thyroid carcinoma is a predominant form of thyroid cancer. Mutations in the BRAF gene, particularly the V600E mutation, is common in PTC and associated with aggressive clinicopathological characteristics and poor prognosis. Genetic testing is performed on tissue to identify patients with the V600E mutation as those patients who are positive for the mutation may benefit from more aggressive therapy.

Method: Next-Generation Sequencing (NGS)

Component Tests Used: n/a

Reference Ranges Used:
Reference ranges for this test are not available online. However, they are included in all test results. For more information, please call us.

Specimen Type: Paraffin-embedded material (FFPE)/Cytology fluids
Volume: n/a

Shipping: room temperature or 4C

Special Instructions: Gene (BRAF, HRAS, KRAS, NRAS, NTRK1, NTRK2, NTRK3, PPARG, RET, TERT Promoter) See requisitions for the full list of available testing and special instructions.

Testing Schedule(s): Please call

Turnaround Time: None

For more information, call 416.340.5227 or 1.866.865.5227